Skip to main content
. Author manuscript; available in PMC: 2013 Nov 1.
Published in final edited form as: Pharm Res. 2012 Jul 4;29(11):3053–3063. doi: 10.1007/s11095-012-0814-5

Fig. 2.

Fig. 2

In vivo anticancer efficacy. (a) Nude mice bearing PC-3 tumors were treated with docetaxel (i.v., 10 or 20 mg/kg) on day 1 and 9 (N=5–6). Bars, SE. (b) Nude mice bearing PC-3/TxR tumors were treated with docetaxel (i.v., 10 or 20 mg/kg) on day 1 and 9, II treatments (p.o., 6.7 mg/kg) once daily, five days a week. (N=4–5). Bars, SE. (c) Nude mice bearing PC-3/TxR tumors were treated with II (p.o., 3.3 mg/kg) twice a day for the first four consecutive days in the first week, and then dosed once daily, five days a week for week 2–4 (N=7), while IAT treatments (p.o., 10 or 30 mg/kg) were twice daily, five days a week for four weeks (N=7). Bars, SE. (d) Nude mice bearing PC-3/TxR tumors were treated with II (p.o., 10 mg/kg) three times a week for four weeks (N5). Bars, SE.